What is PHYLA?
PHYLA is a venture-backed biotechnology firm founded by leading scientists from UCSF and Johns Hopkins University. The company's core mission is to revolutionize the treatment of chronic bacterial diseases through its proprietary microbiome editing technology. By focusing on the intricate balance of the human microbiome, PHYLA aims to create novel therapeutic solutions that offer improved efficacy and safety profiles compared to traditional treatments. Their innovative platform is particularly geared towards addressing persistent dermatological issues like acne and eczema, marking a significant advancement in the field of microbial therapeutics.
How much funding has PHYLA raised?
PHYLA has raised a total of $2M across 1 funding round:
Unspecified
$2M
Unspecified (2022): $2M with participation from N + 1 Ventures, Willow Growth Partners, Progression Fund, and Maximum Effort
Key Investors in PHYLA
N + 1 Ventures
N + 1 Ventures is a multifaceted organization that serves as a people connector, dream accelerator, adventure guide, and founder ally, providing support and guidance to entrepreneurs and leaders.
Willow Growth Partners
Willow Growth Partners is an early-stage capital firm that invests in and supports a diverse group of founders aiming to build transformative consumer brands and technologies.
Progression Fund
Progression Fund is a company that operates in the Venture Capital & Private Equity industry, headquartered in the United States.
What's next for PHYLA?
With the recent major strategic investment, PHYLA is poised for an accelerated growth phase. The enterprise-level funding will likely be directed towards expanding its research and development capabilities, scaling up its platform technology, and potentially initiating clinical trials for its lead product candidates. The company's focus on chronic skin diseases positions it within a substantial market, and this backing provides the necessary resources to further validate its technology and bring its innovative microbiome-based therapies to market. Strategic partnerships and further scientific validation will be key as PHYLA navigates its path towards commercialization.
See full PHYLA company page
